Breast Cancer 18 F-ISO-1 Uptake as a Marker of Proliferation Status.

Autor: McDonald ES; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania elizabeth.mcdonald@pennmedicine.upenn.edu., Doot RK; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Young AJ; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Schubert EK; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Tchou J; Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Pryma DA; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Farwell MD; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Nayak A; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; and., Ziober A; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; and., Feldman MD; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; and., DeMichele A; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Clark AS; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Shah PD; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Lee H; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Carlin SD; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Mach RH; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Mankoff DA; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Jazyk: angličtina
Zdroj: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2020 May; Vol. 61 (5), pp. 665-670. Date of Electronic Publication: 2019 Dec 13.
DOI: 10.2967/jnumed.119.232363
Abstrakt: The σ 2 receptor is a potential in vivo target for measuring proliferative status in cancer. The feasibility of using N -(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1 H )-yl)butyl)-2-(2- 18 F-fluoroethoxy)-5-methylbenzamide ( 18 F-ISO-1) to image solid tumors in lymphoma, breast cancer, and head and neck cancer has been previously established. Here, we report the results of the first dedicated clinical trial of 18 F-ISO-1 in women with primary breast cancer. Our study objective was to determine whether 18 F-ISO-1 PET could provide an in vivo measure of tumor proliferative status, and we hypothesized that uptake would correlate with a tissue-based assay of proliferation, namely Ki-67 expression. Methods: Twenty-eight women with 29 primary invasive breast cancers were prospectively enrolled in a clinical trial (NCT02284919) between March 2015 and January 2017. Each received an injection of 278-527 MBq of 18 F-ISO-1 and then underwent PET/CT imaging of the breasts 50-55 min later. In vivo uptake of 18 F-ISO-1 was quantitated by SUV max and distribution volume ratios and was compared with ex vivo immunohistochemistry for Ki-67. Wilcoxon rank-sum tests assessed uptake differences across Ki-67 thresholds, and Spearman correlation tested associations between uptake and Ki-67. Results: Tumor SUV max (median, 2.0 g/mL; range, 1.3-3.3 g/mL), partial-volume-corrected SUV max , and SUV ratios were tested against Ki-67. Tumors stratified into the high-Ki-67 (≥20%) group had SUV max greater than the low-Ki-67 (<20%) group ( P = 0.02). SUV max exhibited a positive correlation with Ki-67 across all breast cancer subtypes (ρ = 0.46, P = 0.01, n = 29). Partial-volume-corrected SUV max was positively correlated with Ki-67 for invasive ductal carcinoma (ρ = 0.51, P = 0.02, n = 21). Tumor-to-normal-tissue ratios and tumor distribution volume ratio did not correlate with Ki-67 ( P > 0.05). Conclusion: 18 F-ISO-1 uptake in breast cancer modestly correlates with an in vitro assay of proliferation.
(© 2020 by the Society of Nuclear Medicine and Molecular Imaging.)
Databáze: MEDLINE
Externí odkaz: